
Lixte Biotechnology to Present at DealFlow Discovery Conference as LB-100 Clinical Development Advances
Lixte Biotechnology Holdings will participate in the DealFlow Discovery Conference, where CEO Geordan Pursglove will meet with investors while the company advances its first-in-class cancer therapy LB-100 through clinical trials for ovarian clear cell carcinoma and metastatic colon cancer.
Read full story






















